Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human mesenchymal stem cells (Longeveron)
- Development stage
- Phase 2
- Lead developer
- Longeveron
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramyocardial
01
Overview
Human mesenchymal stem cells (hMSCs) are a cell-based biologic therapy investigated for the treatment of non-ischemic dilated cardiomyopathy (NIDCM). Developed by Dr. Joshua M. Hare and his team at the University of Miami's Interdisciplinary Stem Cell Institute, this therapy involves the transendocardial injection of either autologous (patient-derived) or allogeneic (donor-derived) bone marrow-derived mesenchymal stem cells. The cells are delivered via a NOGA catheter system into the left ventricular myocardium. The mechanism of action is primarily attributed to paracrine signaling, where the cells secrete a variety of growth factors and cytokines that promote tissue repair, reduce inflammation through immunomodulatory properties, and stimulate endogenous regenerative processes. This approach aims to improve cardiac function and reverse adverse ventricular remodeling in patients with chronic heart failure due to NIDCM.
- Other names
- hMSCsbone marrow-derived mesenchymal stem cellsLomecel-Bmesenchymal stem cells
Beyond the preview
Go deeper on human mesenchymal stem cells (Longeveron).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human mesenchymal stem cells (Longeveron).